It was observed that the inhibition of Erk1/2 phosphorylation in HNSCC cells through the use of a non-toxic concentration of the Erk inhibitor, ravoxertinib, resulted in the enhancement of the erastin-dependent increase in FaDu and SCC25 cell viability. The gene discussed is MAPK1; the disease is head and neck squamous cell carcinoma.